Cargando…
Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
The aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aeruginosa (PA)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060313/ https://www.ncbi.nlm.nih.gov/pubmed/33883671 http://dx.doi.org/10.1038/s41598-021-88179-7 |
_version_ | 1783681337474940928 |
---|---|
author | Ferreiro, Jose Luis Lamas Otero, Judith Álvarez Rivo, Ana Sanjurjo González, Lucía González Conde, Irene Rodríguez Soneira, María Fernández García, Javier Posada de la Fuente Aguado, Javier |
author_facet | Ferreiro, Jose Luis Lamas Otero, Judith Álvarez Rivo, Ana Sanjurjo González, Lucía González Conde, Irene Rodríguez Soneira, María Fernández García, Javier Posada de la Fuente Aguado, Javier |
author_sort | Ferreiro, Jose Luis Lamas |
collection | PubMed |
description | The aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aeruginosa (PA) infections. This is an observational study. Patients with PA infection treated with continuous piperacillin-tazobactam infusion using elastomeric pumps in our hospital between January 2015 and December 2017 were included. Primary outcomes were mortality during antibiotic treatment and mortality at 30 days. Secondary outcomes were reinfection or relapse at 30 days and clinical cure rate. The cost of each episode was compared with theoretical cost of the same treatment using conventional hospitalization. 35 patients were included. One patient (2.9%) died during the treatment. Overall 30-day mortality was 5.7%. No death was related to infection by PA. One patient (2.9%) had a reinfection at 30 days. Cure was achieved in 93% of patients at the end of treatment. There were no severe complications related to elastomeric pumps. Treatment cost with outpatient antimicrobial therapy was 67% lower than theoretical cost with conventional hospital treatment. Oupatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps in patients with PA infections is safe and effective with lower costs. |
format | Online Article Text |
id | pubmed-8060313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80603132021-04-22 Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection Ferreiro, Jose Luis Lamas Otero, Judith Álvarez Rivo, Ana Sanjurjo González, Lucía González Conde, Irene Rodríguez Soneira, María Fernández García, Javier Posada de la Fuente Aguado, Javier Sci Rep Article The aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aeruginosa (PA) infections. This is an observational study. Patients with PA infection treated with continuous piperacillin-tazobactam infusion using elastomeric pumps in our hospital between January 2015 and December 2017 were included. Primary outcomes were mortality during antibiotic treatment and mortality at 30 days. Secondary outcomes were reinfection or relapse at 30 days and clinical cure rate. The cost of each episode was compared with theoretical cost of the same treatment using conventional hospitalization. 35 patients were included. One patient (2.9%) died during the treatment. Overall 30-day mortality was 5.7%. No death was related to infection by PA. One patient (2.9%) had a reinfection at 30 days. Cure was achieved in 93% of patients at the end of treatment. There were no severe complications related to elastomeric pumps. Treatment cost with outpatient antimicrobial therapy was 67% lower than theoretical cost with conventional hospital treatment. Oupatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps in patients with PA infections is safe and effective with lower costs. Nature Publishing Group UK 2021-04-21 /pmc/articles/PMC8060313/ /pubmed/33883671 http://dx.doi.org/10.1038/s41598-021-88179-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ferreiro, Jose Luis Lamas Otero, Judith Álvarez Rivo, Ana Sanjurjo González, Lucía González Conde, Irene Rodríguez Soneira, María Fernández García, Javier Posada de la Fuente Aguado, Javier Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection |
title | Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection |
title_full | Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection |
title_fullStr | Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection |
title_full_unstemmed | Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection |
title_short | Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection |
title_sort | outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with pseudomonas aeruginosa infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060313/ https://www.ncbi.nlm.nih.gov/pubmed/33883671 http://dx.doi.org/10.1038/s41598-021-88179-7 |
work_keys_str_mv | AT ferreirojoseluislamas outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT oterojudithalvarez outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT rivoanasanjurjo outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT gonzalezluciagonzalez outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT condeirenerodriguez outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT soneiramariafernandez outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT garciajavierposada outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT delafuenteaguadojavier outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection |